Transforming growth factor‐beta (TGF‐β) expression and interaction with proteinase 3 (PR3) in anti‐neutrophil cytoplasmic antibody (ANCA)‐associated vasculitis

TGF‐β is a multifunctional cytokine modulating the onset and course of autoimmune diseases as shown in experimental models. The aim of this study was to investigate TGF‐β expression in ANCA‐associated vasculitis (AAV), and the possible interactions of this cytokine with lysosomal enzymes identified as ANCA autoantigens (e.g. PR3). This included TGF‐β effects on the translocation of the lysosomal enzymes to the cell surface of polymorphonuclear neutrophils (PMN), and the presumed activation of non‐bioactive, latent TGF‐β by these enzymes. Patients with various types of systemic vasculitis (SV) were studied, including three different types of AAV (Wegener's granulomatosis (WG), Churg–Strauß syndrome (CSS) and microscopic polyangiitis (MPA)). Regardless of the type of assay applied, the TGF‐β1 isoform was found to be overexpressed in SV, including AAV, and to correlate with disease activity as shown for WG. Mean TGF‐β1 plasma levels in AAV patients ranged from 8.9 ng/ml (WG) to 13.3 ng/ml (CSS) (control 4.2 ng/ml; P < 0.01), while TGF‐β2 levels were not elevated. Flow cytometry analysis showed TGF‐β1 to be a potent translocation factor for PR3 comparable to other neutrophil‐activating factors such as IL‐8. PR3 membrane expression on primed PMN increased by up to 51% after incubation with TGF‐β1. PR3 itself was revealed as a potent activator of latent TGF‐β, thus mediating bioeffects of this cytokine. These findings, together with other features of TGF‐β such as induction of angiogenesis and its strong chemotactic capacity, indicate that TGF‐β might serve as a proinflammatory factor in SV, especially in AAV.

[1]  W. Gross,et al.  Immunodiagnostic and pathophysiologic aspects of antineutrophil cytoplasmic antibodies in vasculitis , 1995, Current opinion in rheumatology.

[2]  U. Helmchen,et al.  Antineutrophil cytoplasmic autoantibodies, autoantigens, and systemic vasculitis , 1995, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[3]  M. Cassatella The production of cytokines by polymorphonuclear neutrophils. , 1995, Immunology today.

[4]  W. Gross,et al.  Determination of transforming growth factor beta 2 in human blood samples by ELISA. , 1995, JIM - Journal of Immunological Methods.

[5]  W. Border,et al.  Transforming Growth Factor β in Tissue Fibrosis , 1994 .

[6]  M. Heller,et al.  Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. , 1994, Arthritis and rheumatism.

[7]  P. Roux‐Lombard,et al.  Elevated serum levels of TNF soluble receptors in patients with positive anti-neutrophil cytoplasmic antibodies. , 1994, British journal of rheumatology.

[8]  M. Ernst,et al.  Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo , 1994, Clinical and experimental immunology.

[9]  S. Wahl,et al.  Transforming growth factor beta: a matter of life and death. , 1994, Journal of leukocyte biology.

[10]  W. Gross New developments in the treatment of systemic vasculitis. , 1994, Current opinion in rheumatology.

[11]  M. Daha,et al.  Cleavage and inactivation of human C1 inhibitor by the human leukocyte proteinase, proteinase 3 , 1993, European journal of immunology.

[12]  W. L. Gross,et al.  The clinical relevance of ANCA in vasculitis , 1993, Clinical and experimental immunology.

[13]  W. Gross,et al.  'Classic' anti-neutrophil cytoplasmic autoantibodies (cANCA), 'Wegener's autoantigen' and their immunopathogenic role in Wegener's granulomatosis. , 1993, Journal of autoimmunity.

[14]  T. Hada,et al.  Local production and localization of transforming growth factor‐beta in tuberculous pleurisy , 1993, Clinical and experimental immunology.

[15]  E. Csernok,et al.  ANCA and associated diseases: immunodiagnostic and pathogenetic aspects , 1993, Clinical and experimental immunology.

[16]  S. Wahl,et al.  Reversal of acute and chronic synovial inflammation by anti- transforming growth factor beta , 1993, The Journal of experimental medicine.

[17]  Stacey Schul tz-Cherry Thrombospondin Causes Activation of Latent Transforming Growth Factor-Secreted by Endothelial Cells by a Novel Mechanism , 2002 .

[18]  E. Ruoslahti,et al.  Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease , 1992, Nature.

[19]  P. Kondaiah,et al.  Autocrine induction of tumor protease production and invasion by a metallothionein‐regulated TGF‐beta 1 (Ser223, 225). , 1992, The EMBO journal.

[20]  S. Wahl Transforming growth factor beta (TGF-beta) in inflammation: a cause and a cure. , 1992, Journal of clinical immunology.

[21]  J. Massagué,et al.  Transforming growth factor-beta. , 1992, Cancer surveys.

[22]  S. Wahl The role of transforming growth factor-beta in inflammatory processes , 1991 .

[23]  R. Winchurch,et al.  Pathologic concentrations of interleukin 6 inhibit T cell responses via induction of activation of TGF‐β , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  J. Kelley,et al.  A rapid colorimetric bioassay for transforming growth factor beta (TGF-beta) using a microwell plate reader. , 1991, Journal of immunological methods.

[25]  R. Goldschmeding,et al.  Autoimmunity to lysosomal enzymes: new clues to vasculitis and glomerulonephritis? , 1991, Immunology today.

[26]  D. Bainton,et al.  Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis. , 1990, The American journal of pathology.

[27]  N. Shibata,et al.  Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis , 1990, Clinical and experimental immunology.

[28]  M. Sporn,et al.  Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1 , 1990, Nature.

[29]  M. Lotz,et al.  Transforming growth factor-beta and cellular immune responses in synovial fluids. , 1990, Journal of immunology.

[30]  H. Moses,et al.  Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin , 1990, The Journal of cell biology.

[31]  H. Koeppen,et al.  A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Lüdemann,et al.  Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme , 1990, The Journal of experimental medicine.

[33]  S. Wahl,et al.  Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta , 1990, The Journal of experimental medicine.

[34]  H. Moses,et al.  Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium , 1988, The Journal of cell biology.

[35]  C. Dinarello,et al.  Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibodies. , 1986, The Journal of clinical investigation.

[36]  M. Sporn,et al.  Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.